rs1548731
Variant names:
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BP4_Strong
The NM_138636.5(TLR8):c.3+3119T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.64 ( 17020 hom., 21314 hem., cov: 23)
Failed GnomAD Quality Control
Consequence
TLR8
NM_138636.5 intron
NM_138636.5 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.289
Publications
19 publications found
Genes affected
TLR8 (HGNC:15632): (toll like receptor 8) The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. This gene is predominantly expressed in lung and peripheral blood leukocytes, and lies in close proximity to another family member, TLR7, on chromosome X. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -4 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| TLR8 | NM_138636.5 | c.3+3119T>C | intron_variant | Intron 1 of 1 | ENST00000218032.7 | NP_619542.1 | ||
| TLR8 | NM_016610.4 | c.-80-478T>C | intron_variant | Intron 1 of 2 | NP_057694.2 | |||
| TLR8-AS1 | NR_030727.1 | n.241-1495A>G | intron_variant | Intron 2 of 4 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.641 AC: 70960AN: 110774Hom.: 17026 Cov.: 23 show subpopulations
GnomAD3 genomes
AF:
AC:
70960
AN:
110774
Hom.:
Cov.:
23
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Data not reliable, filtered out with message: InbreedingCoeff AF: 0.640 AC: 70983AN: 110828Hom.: 17020 Cov.: 23 AF XY: 0.645 AC XY: 21314AN XY: 33034 show subpopulations
GnomAD4 genome
Data not reliable, filtered out with message: InbreedingCoeff
AF:
AC:
70983
AN:
110828
Hom.:
Cov.:
23
AF XY:
AC XY:
21314
AN XY:
33034
show subpopulations
African (AFR)
AF:
AC:
11785
AN:
30509
American (AMR)
AF:
AC:
8001
AN:
10448
Ashkenazi Jewish (ASJ)
AF:
AC:
1831
AN:
2645
East Asian (EAS)
AF:
AC:
3435
AN:
3550
South Asian (SAS)
AF:
AC:
2241
AN:
2640
European-Finnish (FIN)
AF:
AC:
4046
AN:
5803
Middle Eastern (MID)
AF:
AC:
148
AN:
215
European-Non Finnish (NFE)
AF:
AC:
38029
AN:
52840
Other (OTH)
AF:
AC:
996
AN:
1495
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
832
1664
2496
3328
4160
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
650
1300
1950
2600
3250
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.